JP7361031B2 - ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 - Google Patents

ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 Download PDF

Info

Publication number
JP7361031B2
JP7361031B2 JP2020527921A JP2020527921A JP7361031B2 JP 7361031 B2 JP7361031 B2 JP 7361031B2 JP 2020527921 A JP2020527921 A JP 2020527921A JP 2020527921 A JP2020527921 A JP 2020527921A JP 7361031 B2 JP7361031 B2 JP 7361031B2
Authority
JP
Japan
Prior art keywords
trkb
rat
human
endogenous
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020527921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021508236A5 (enExample
JP2021508236A (ja
Inventor
アレクサンダー オー． ムジカ，
ヤジュン タン，
ジェフリー ディー． リー，
ミン ガオ，
スーザン クロール，
リン マクドナルド，
イン フー，
カーメロ ロマーノ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021508236A publication Critical patent/JP2021508236A/ja
Publication of JP2021508236A5 publication Critical patent/JP2021508236A5/ja
Priority to JP2023171306A priority Critical patent/JP7610672B2/ja
Application granted granted Critical
Publication of JP7361031B2 publication Critical patent/JP7361031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020527921A 2017-11-30 2018-11-30 ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 Active JP7361031B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023171306A JP7610672B2 (ja) 2017-11-30 2023-10-02 ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762592905P 2017-11-30 2017-11-30
US62/592,905 2017-11-30
US201862661373P 2018-04-23 2018-04-23
US62/661,373 2018-04-23
PCT/US2018/063390 WO2019108983A1 (en) 2017-11-30 2018-11-30 Non-human animals comprising a humanized trkb locus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023171306A Division JP7610672B2 (ja) 2017-11-30 2023-10-02 ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物

Publications (3)

Publication Number Publication Date
JP2021508236A JP2021508236A (ja) 2021-03-04
JP2021508236A5 JP2021508236A5 (enExample) 2021-12-16
JP7361031B2 true JP7361031B2 (ja) 2023-10-13

Family

ID=64734209

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020527921A Active JP7361031B2 (ja) 2017-11-30 2018-11-30 ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
JP2023171306A Active JP7610672B2 (ja) 2017-11-30 2023-10-02 ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023171306A Active JP7610672B2 (ja) 2017-11-30 2023-10-02 ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物

Country Status (11)

Country Link
US (2) US11419318B2 (enExample)
EP (2) EP4299732A3 (enExample)
JP (2) JP7361031B2 (enExample)
KR (1) KR102709884B1 (enExample)
CN (2) CN111655031B (enExample)
AU (2) AU2018375796B2 (enExample)
CA (1) CA3076377A1 (enExample)
ES (1) ES2973937T3 (enExample)
IL (2) IL310006A (enExample)
SG (1) SG11202002456WA (enExample)
WO (1) WO2019108983A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
HUE067361T2 (hu) 2018-07-16 2024-10-28 Regeneron Pharma Ditra betegség rágcsáló modelljei és alkalmazásaik
WO2020179844A1 (ja) * 2019-03-04 2020-09-10 公益財団法人東京都医学総合研究所 Ｔｒｋ断片をコードする核酸構築物、及びその利用
WO2021158883A1 (en) * 2020-02-07 2021-08-12 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160157470A1 (en) 2014-12-05 2016-06-09 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
JP2016539655A (ja) 2013-12-11 2016-12-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
WO1999005266A2 (en) 1997-07-26 1999-02-04 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
AU2001273245A1 (en) 2000-07-05 2002-01-14 Pangene Corporation Modulators of trk protein activity, compositions and uses
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7060429B2 (en) * 2001-02-22 2006-06-13 University Of Maryland, Baltimore Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
AUPR451401A0 (en) 2001-04-20 2001-05-24 Monash University A method of nuclear transfer
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
CN101117633B (zh) 2006-08-03 2011-07-20 上海交通大学附属儿童医院 一种细胞核移植方法
CN101157730A (zh) 2006-09-25 2008-04-09 南方医科大学珠江医院 一种携带神经营养因子穿过血脑屏障的融合蛋白及其编码基因与用途
JP2011501760A (ja) 2007-10-23 2011-01-13 ノバルティス アーゲー 呼吸器疾患の処置のためのｔｒｋｂ抗体の使用
KR20100120226A (ko) 2008-04-11 2010-11-12 유티씨 파워 코포레이션 매니폴드 섬프를 갖는 바이폴라 플레이트 및 연료 전지
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
TR201903376T4 (tr) 2009-10-29 2019-04-22 Regeneron Pharma Çok fonksiyonlu alleller.
SG10201510056SA (en) 2011-10-28 2016-01-28 Regeneron Pharma Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
RU2751240C2 (ru) 2011-10-28 2021-07-12 Регенерон Фармасьютикалс, Инк. Гуманизированные il-6 и рецептор il-6
KR102295746B1 (ko) 2011-10-28 2021-09-01 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
JP6275120B2 (ja) 2012-04-25 2018-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 大きい標的化ベクターによるヌクレアーゼ媒介標的化
FI3597749T3 (fi) 2012-05-25 2023-10-09 Univ California Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten
WO2014033644A2 (en) 2012-08-28 2014-03-06 Novartis Ag Methods of nuclease-based genetic engineering
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
PT3363902T (pt) 2012-12-06 2019-12-19 Sigma Aldrich Co Llc Modificação e regulação de genoma baseadas em crispr
JP6475172B2 (ja) 2013-02-20 2019-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットの遺伝子組換え
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
JP6444321B2 (ja) 2013-02-22 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化主要組織適合性遺伝子複合体を発現するマウス
EP3456831B1 (en) 2013-04-16 2021-07-14 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
SMT202500280T1 (it) 2013-09-23 2025-09-12 Regeneron Pharma Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale
EP3071024B1 (en) 2013-11-19 2018-09-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
EP3430898A1 (en) 2013-11-19 2019-01-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
US10370692B2 (en) 2013-12-20 2019-08-06 Hoffmann-La Roche Inc. Recombinant polypeptide production methods
HK1231374A1 (zh) * 2014-02-21 2017-12-22 Regeneron Pharmaceuticals, Inc. 用於靶抗原的细胞特异性调变的方法、组合物和试剂盒
SMT202000332T1 (it) 2014-04-08 2020-07-08 Regeneron Pharma Animali non umani aventi recettori fc-gamma umanizzati
NO2785538T3 (enExample) 2014-05-07 2018-08-04
EP3143043B1 (en) * 2014-05-16 2022-12-14 Pfizer Inc. Bispecific antibodies with engineered ch1-cl interfaces
KR102821645B1 (ko) 2014-05-19 2025-06-19 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
DK3157956T3 (da) 2014-06-19 2020-04-27 Regeneron Pharma Ikke-humane dyr med et humaniseret gen med programmeret celledød 1
MX384887B (es) 2014-06-23 2025-03-14 Regeneron Pharma Ensamblaje de adn mediado por nucleasa.
SG10201911411YA (en) 2014-06-26 2020-02-27 Regeneron Pharma Methods and compositions for targeted genetic modifications and methods of use
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
KR20170083534A (ko) * 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
CA3176380A1 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
BR112017010793A2 (pt) 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
EP4399969A3 (en) 2014-12-09 2024-10-30 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
AU2016246698B2 (en) 2015-04-06 2022-06-02 Regeneron Pharmaceuticals, Inc. Humanized T cell mediated immune responses in non-human animals
MX2020003550A (es) * 2017-11-30 2020-08-03 Regeneron Pharma Anticuerpos monoclonales anti-trkb y metodos de uso.
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
HUE067361T2 (hu) 2018-07-16 2024-10-28 Regeneron Pharma Ditra betegség rágcsáló modelljei és alkalmazásaik

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539655A (ja) 2013-12-11 2016-12-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
US20160157470A1 (en) 2014-12-05 2016-06-09 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
US20160345549A1 (en) 2014-12-05 2016-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BUROVA E; ET AL，MOLECULAR CANCER THERAPEUTICS，2017年03月06日，VOL:16, NR:5，PAGE(S):861 - 870，http://dx.doi.org/10.1158/1535-7163.MCT-16-0665
DANIEL HARARI; ET AL，BRIDGING THE SPECIES DIVIDE: TRANSGENIC MICE HUMANIZED FOR TYPE-I INTERFERON RESPONSE，PLOS ONE，2014年01月09日，VOL:9, NR:1，PAGE(S): 1(E84259) - 12(E84259)，http://dx.doi.org/10.1371/journal.pone.0084259
DIETMAR HERNDLER-BRANDSTETTER; ET AL，PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES，米国，NATIONAL ACADEMY OF SCIENCES，2017年10月25日，VOL:114, NR:45，PAGE(S):E9626 - E9634，http://dx.doi.org/10.1073/pnas.1705301114
Eija KOPONEN et al.，"Transgenic mice overexpressing the full-length neurotrophin receptor trkB exhibit increasedactivation of the trkB-PLCγpathway, reduced anxiety, and facilitated learning"，Molecular and Cellular Neuroscience，2004年05月，Vol. 26, No. 1，p.166-181，DOI: 10.1016/j.mcn.2004.01.006
JOHN C LIN; ET AL，PLOS ONE，2008年04月02日，VOL:3, NR:4，PAGE(S): 1(E1900) - 7(E1900)，http://dx.doi.org/10.1371/journal.pone.0001900
LUIKART B W; ET AL，IN VIVO ROLE OF TRUNCATED TRKB RECEPTORS DURING SENSORY GANGLION NEUROGENESIS，NEUROSCIENCE，米国，2003年04月10日，VOL:117, NR:4，PAGE(S):847 - 858，http://dx.doi.org/10.1016/S0306-4522(02)00719-4
MYLENE PERREAULT; ET AL，PLOS ONE，2013年05月20日，VOL:8, NR:5，PAGE(S): 1(E62616) - 13(E62616)，http://dx.doi.org/10.1371/journal.pone.0062616

Also Published As

Publication number Publication date
JP2024009849A (ja) 2024-01-23
SG11202002456WA (en) 2020-04-29
ES2973937T3 (es) 2024-06-25
IL310006A (en) 2024-03-01
US12396444B2 (en) 2025-08-26
US20190159436A1 (en) 2019-05-30
AU2025200858A1 (en) 2025-02-27
IL274740A (en) 2020-07-30
RU2020113566A (ru) 2021-12-30
RU2020113566A3 (enExample) 2022-02-10
AU2018375796A1 (en) 2020-04-23
EP4299732A2 (en) 2024-01-03
EP3585164A1 (en) 2020-01-01
US11419318B2 (en) 2022-08-23
EP3585164C0 (en) 2023-12-27
JP2021508236A (ja) 2021-03-04
AU2018375796B2 (en) 2024-11-21
EP4299732A3 (en) 2024-03-27
IL274740B1 (en) 2024-02-01
KR102709884B1 (ko) 2024-09-26
CA3076377A1 (en) 2019-06-06
EP3585164B1 (en) 2023-12-27
CN111655031B (zh) 2022-11-18
US20220361464A1 (en) 2022-11-17
WO2019108983A1 (en) 2019-06-06
KR20200090770A (ko) 2020-07-29
CN116064611A (zh) 2023-05-05
JP7610672B2 (ja) 2025-01-08
IL274740B2 (en) 2024-06-01
CN111655031A (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
JP7610672B2 (ja) ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
JP7770368B2 (ja) ヒト化ａｓｇｒ１座位を含む非ヒト動物
AU2018338790A1 (en) Non-human animals comprising a humanized TTR locus and methods of use
US20230081547A1 (en) Non-human animals comprising a humanized klkb1 locus and methods of use
RU2800428C2 (ru) НЕ ЯВЛЯЮЩИЕСЯ ЧЕЛОВЕКОМ ЖИВОТНЫЕ, СОДЕРЖАЩИЕ ГУМАНИЗИРОВАННЫЙ ЛОКУС TrkB
HK40104014A (en) Rats comprising a humanized trkb locus
HK40017997B (en) Rats comprising a humanized trkb locus
HK40017997A (en) Rats comprising a humanized trkb locus
HK40018461A (en) Rodents comprising a humanized asgr1 locus
HK40018461B (en) Rodents comprising a humanized asgr1 locus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231002

R150 Certificate of patent or registration of utility model

Ref document number: 7361031

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150